MILAN (Reuters) – Thermo Fisher Scientific (NYSE 🙂 said Thursday it would work Pfizer (NYSE 🙂 and BioNtech produce their COVID-19 vaccine in Italy.
"Thermo Fisher operates as part of Pfizer's global vaccine manufacturing network and will provide manufacturing services in Italy for the Pfizer-BioNTech COVID-19 vaccine, which is sold in multiple markets," the company said in an email statement.
Thermo Fisher added that in 2021 the company will provide sterile filling and finished product manufacturing services at its facility in Monza, near Milan.
Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. As a result, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.
Fusion Media or any person involved with Fusion Media assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.